Australian Defence Force Selects GA-ASI’s MQ-9B for Project Air 7003
5.12.2019 04:28:00 EET | Business Wire | Press release
General Atomics Aeronautical Systems, Inc. (GA-ASI), the world’s leading manufacturer of Remotely Piloted Aircraft Systems (RPAS), has been advised that the Australian Government has selected GA-ASI’s MQ-9B SkyGuardian® variant to provide the Armed RPAS for the Australian Defence Force (ADF) under Project Air 7003. This follows the Government’s announcement in November 2018 that GA-ASI would provide Armed RPAS to the ADF. The ADF expects to take first delivery in the early 2020s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005989/en/
The Australian Government selected GA-ASI’s MQ-9B SkyGuardian® variant to provide the Armed RPAS for the Australian Defence Force under Project Air 7003. (Photo: Business Wire)
“We have worked closely with the ADF to determine the right RPAS to meet their needs,” said Linden Blue, CEO, GA-ASI. “MQ-9B will provide the all-weather, multi-mission support, and interoperability that the ADF requires. We look forward to working closely with our Australian industry partners to provide a highly capable RPAS to the ADF, while creating high-tech jobs in Australia.”
The ADF joins other top-tier military forces in choosing a GA-ASI RPAS because of its proven multi-role combat performance. MQ-9B is part of GA-ASI’s Predator® series of RPAS, which is the world’s most trusted and capable armed Medium-altitude, Long-endurance (MALE) RPAS, and hails from a family of aircraft that has flown more than six million flight hours.
The UK Royal Air Force (RAF) is acquiring the MQ-9B as part of its Protector RG Mk1 program and is scheduled for first delivery in the early 2020s. The Government of Belgium has approved Belgian Defense to negotiate for the acquisition of MQ-9B to meet the nation’s RPA requirements.
MQ-9B development is the result of a five-year, company funded program to deliver an unmanned aircraft system to meet the stringent airworthiness type-certification requirements of NATO and civil aviation authorities throughout the world. MQ-9B is provisioned for the GA-ASI-developed Detect and Avoid (DAA) system, which consists of air-to-air radar, Traffic alert and Collision Avoidance System (TCAS II), and Automatic Dependent Surveillance-Broadcast (ADS-B). The MQ-9B is built for all-weather performance with lightning protection, damage tolerance, and de-icing system.
GA-ASI announced its intention to offer a MALE RPAS to the ADF during AVALON 2017 with the launch of Team Reaper Australia, a robust group of Australian industry partners. The team currently consists of ten world-class Australian companies providing a range of innovative sensor, communication, manufacturing and life-cycle support capabilities including Cobham (lead industry partner), CAE, Raytheon, Flight Data Systems, TAE Aerospace, Quickstep, AirSpeed, Collins Aerospace, Ultra, and SentientVision.
Hi-resolution images of the MQ-9B SkyGuardian are available to qualified media outlets from the GA-ASI media contact list.
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With nearly 6 million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.
Predator, SkyGuardian and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005989/en/
Contact information
Steven Henden
General Atomics Aeronautical Systems, Inc.
+1 (858) 524-8101
ASI-MediaRelations@ga-asi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom